Abstract
Contrast-enhanced ultrasound (CEUS) with quantitative parametric imaging is currently not recommended for the detection of prostate cancer (PCa). Meanwhile, multiparametric magnetic resonance imaging (mpMRI)-targeted biopsy (TBx) has evolved as an alternative to systematic transrectal ultrasound (TRUS)-guided biopsy (SBx). However, mpMRI before first biopsy remains controversial. In this prospective trial, we compared clinically significant (cs)PCa detection rates for MRI-TBx and CEUS-TBx with standard SBx in biopsy-naive men.
| Original language | English |
|---|---|
| Pages (from-to) | e430-e430 |
| Number of pages | 1 |
| Journal | Journal of Urology |
| Volume | 201 |
| Issue number | 4S |
| DOIs | |
| Publication status | Published - 1 Apr 2019 |
| Event | 114th American Urological Association Annual Meeting - Chicago, United States Duration: 3 May 2019 → 6 May 2019 http://www.aua2019.org/ |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Multiparametric mri- and contrast enhanced ultrasound-targeted biopsy for the detection of significant prostate cancer: can we replace systematic biopsy?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver